In collaboration with our research partners at the University of Bristol, we have had a manuscript detailing the results of our preclinical studies of PN6047 accepted for publication in the highly cited Journal of Experimental Pharmacology and Therapeutics (JPET), the official journal of the American Society for Pharmacology and Experimental Therapeutics (ASPET).

We are delighted to have this peer-reviewed validation of our candidate compound made available for the Biomedical community to read and digest and we are confident that it will reignite interest in the potential value of biased signalling delta opioid receptor agonists for the treatment of a variety of conditions including our key target of neuropathic pain and for others including migraine, anxiety and depression and chronic cough. Details of the article which will soon be available electronically in advance of the printed version are shown below:

Title: A novel G protein-biased agonist at the δ opioid receptor with analgesic efficacy in models of chronic pain.
First Author: Dr Alexandra Conibear (Research Associate, School of Physiology, Pharmacology & Neuroscience, University of Bristol) with Corresponding Author Professor Eamonn Kelly, University of Bristol.